Glycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein
Biotechnology and Bioengineering · 2026
DOI: 10.1002/bit.70285 ↗At a glance
Journal article in Biotechnology and Bioengineering, 2026. Written by Frances Rocamora and 12 co-authors. Institution: Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California, USA. Major MEDLINE topics: alpha 1-Antitrypsin, Recombinant Proteins, Protein Engineering. 32 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NHLBI NIH HHS, Novo Nordisk Foundation, Novo Nordisk Fonden.
Abstract (original language)
Alpha‐1‐antitrypsin (A1AT) is a multifunctional, clinically important, high‐value therapeutic glycoprotein that can be used for the treatment of many diseases, such as A1AT deficiency, diabetes, graft‐versus‐host disease, cystic fibrosis, and various viral infections. Currently, the only U.S. food and drug administration‐approved treatment for A1AT disorders is intravenous augmentation therapy with human plasma‐derived A1AT (pdA1AT). In addition to its limited supply, this approach poses a risk of infection transmission, since it uses therapeutic A1AT harvested from donors. To address these issues, we sought to generate recombinant human A1AT (rhA1AT) that is comparable to its plasma‐derived counterpart using glycoengineered Chinese Hamster Ovary (geCHO‐L) cells. By perturbing nine key genes that are part of the CHO glycosylation machinery and expressing the human ST6GAL1 and A1AT genes, we obtained stable, high producing geCHO‐L lines that produced rhA1AT having a highly similar glycoprofile to pdA1AT. Additionally, the rhA1AT demonstrated in vitro activity and in vivo half‐life comparable to commercial pdA1AT. Thus, we anticipate that this platform will help produce human‐like recombinant plasma proteins, thereby providing a more sustainable and reliable source of therapeutics that are cost‐effective and better‐controlled regarding purity, clinical safety, and quality.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pediatrics, School of Medicine, University of California, San Diego, La Jolla, California, USA.
- Complex Carbohydrate Research Center, University of Georgia, Athens, Georgia, USA.
- Center for Molecular Medicine, University of Georgia, Athens, Georgia, USA.
- Department of Biotechnology and Biomedicine, National Biologics Facility, Technical University of Denmark, Lyngby, Denmark.
- Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, Maryland, USA.
- NeuImmune, Inc., Sykesville, Maryland, USA.
ORCID profiles: Thomas E Cleveland, Nathan E Lewis
Funding
- NHLBI NIH HHS
- Novo Nordisk Foundation
- Novo Nordisk Fonden
- National Heart, Lung, and Blood Institute
Cite
APA
Rocamora, F., Hsieh, C. L., Schoffelen, S., Arnsdorf, J., Toth, E. A., Yunus, A. S., Cleveland, T. E., Bjørn, S. P., Wu, M. Y. M., McElvaney, N. G., Voldborg, B. G. R., Fuerst, T. R., & Lewis, N. E. (2026). Glycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein. Biotechnology and Bioengineering. https://doi.org/10.1002/bit.70285
Vancouver
Rocamora F, Hsieh CL, Schoffelen S, Arnsdorf J, Toth EA, Yunus AS, et al. Glycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein. Biotechnology and Bioengineering. 2026. doi:10.1002/bit.70285
BibTeX
@article{Rocamora2026,
author = {Rocamora, Frances and Hsieh, Chen-Lin and Schoffelen, Sanne and Arnsdorf, Johnny and Toth, Eric A and Yunus, Abdul S and Cleveland, Thomas E and Bjørn, Sara Petersen and Wu, Mina Ying Min and McElvaney, Noel G and Voldborg, Bjørn Gunnar Rude and Fuerst, Thomas R and Lewis, Nathan E},
title = {Glycoengineered Recombinant Alpha1‐Antitrypsin Results in Comparable In Vitro and In Vivo Activities to Human Plasma‐Derived Protein},
journal = {Biotechnology and Bioengineering},
year = {2026},
doi = {10.1002/bit.70285}
}
EUVIMED